VJOncology is committed to improving our service to you

ASCO 2019 | Palbociclib & fulvestrant for breast cancer

VJOncology is committed to improving our service to you

Ramon De Mello

Ramon De Mello, MD, PhD, FACP, of the University of Algarve, Faro, Portugal, gives an updates on the PALOMA-3 study, a Phase III clinical trial with the primary objective of demonstrating the superiority of palbociclib in combination with fulvestrant over fulvestrant alone in prolonging PFS in women with HR+, HER2 negative metastatic breast cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter